Accepting new patients
Jonathan Goldman, MD
(he/him) - Medical Oncology|
- Thoracic Medical Oncology
Average rating:
4.9
Santa Monica Cancer Care
|
2020 Santa Monica Boulevard,
Suite 600,
Santa Monica, CA
90404
About
Jonathan W. Goldman, M.D. is a Professor of Medicine at UCLA in the Hematology/Oncology Division. He is the UCLA Director of Clinical Trials in Thoracic Oncology and the Associate Director of Early Drug Development, and the Chair of University of California Lung Cancer Consortium. His research focuses on the development of new treatments for lung and other solid cancers. Most recently he has been investigating novel antibody-drug conjugates, small cell lung cancer therapies, and combination targeted therapies.
Languages
Education
Fellowship
Hematology & Oncology, UCLA School of Medicine, 2008
Residency
UC San Francisco School of Medicine, 2004
Internship
Internal Medicine, UC San Francisco School of Medicine, 2002
Related Clinical Trials
Locations
Hospital Affiliations
Ronald Reagan UCLA Medical Center
UCLA Santa Monica Medical Center
Medical Services
Areas of Focus
Videos
Treatment for Lung Cancer
Research
Interests
Lung cancer, targeted therapy, immune therapy.
Publications
- Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 Aug 27;383(9):825-835. doi: 10.1056/NEJMoa2005651. PubMed PMID: 32846061.
- Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Oct 29;383(18):17111723. doi: 0.1056/NEJMoa2027071. Epub 2020 Sep 19. PubMed PMID: 32955177.
- Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJM oa2304594. Epub 2023 Jun 4. PubMed PMID: 37272535.
- Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8. PubMed PMID: 37937763.
- Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21. PubMed PMID: 37870976.
Insurance
- Aetna
- Anthem Blue Cross
- Blue Shield of California
- Centivo
- Cigna
- First Health
- Health Net of California
- Interplan (part of HealthSmart)
- L.A. Care
- Medicare Advantage
- MultiPlan
- UFCM Health System
- Prime Health Services
- Private Healthcare Systems (PHCS)
- TRICARE
- UnitedHealthcare
The list of health care plans above may not be comprehensive and could change.
Please contact your benefits coordinator or health insurance company directly to verify coverage.
Visit our health insurance information page for more details.
Links
Reviews
Overall Rating:
4.9
249 total ratings | 27 reviews
5.0
January 29, 2025
Informed, Supportive, caring.
5.0
January 17, 2025
First time using the video which is very clear and easy listening to the doctor
5.0
January 15, 2025
My experience with the doctor was very helpful and informative and I felt very comfortable
5.0
January 14, 2025
Dr. Goldman is open to shared decision making after discussing my cancer trajectory and thoughtfully makes the appropriate referrals for me.
5.0
January 14, 2025
Dr. Goldman is a very kind, thorough, patient, compassionate physician. He explained my results and answered all my questions. He is a wonderful doctor.